- Amended Current report filing (8-K/A)
17 Dicembre 2009 - 7:52PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K/A
(Amendment
No. 2)
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
September
20, 2009 (Date of report)
CARACO
PHARMACEUTICAL LABORATORIES, LTD.
(Exact
name of registrant as specified in its charter)
|
Michigan
|
|
1-31773
|
|
38-2505723
|
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
file number)
|
|
(I.R.S.
employer identification no.)
|
1150 Elijah McCoy Drive,
Detroit, Michigan 48202
(Address
of principal executive offices)
(313)
871-8400
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
140.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item
5.02. Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
The
Company is filing this Amendment No. 2 to the Current Report on Form 8-K filed
on September 23, 2009 (the “Form 8-K”) solely to include, as Exhibit 17.3,
Georges Ugeux’s additional response to the disclosures in the Form
8-K
Item
9.01. Financial Statements and Exhibits
|
17.1
|
Letter
of resignation of Georges Ugeux dated September 20, 2009 (previously filed
as Exhibit 99.1 to the Form 8-K filed on September 23,
2009).
|
|
17.2
|
Response
Letter (e-mail correspondence) of Georges Ugeux dated September 23, 2009
(previously filed in Amendment No. 1 to the Form 8-K filed on September
25, 2009).
|
|
17.3
|
Response
Letter (e-mail correspondence) of Georges Ugeux dated December 16,
2009.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
CARACO
PHARMACEUTICAL LABORATORIES, LTD.
|
Date: December
17, 2009
|
By:
|
/s/
Jitendra N. Doshi
|
|
|
|
Jitendra
N. Doshi
|
|
|
|
Chief
Executive Officer
|
|
Exhibit
Index
|
17.1
|
Letter
of resignation of Georges Ugeux dated September 20, 2009 (previously filed
as Exhibit 99.1 to the Form 8-K filed on September 23,
2009).
|
|
17.2
|
Response
Letter (e-mail correspondence) of Georges Ugeux dated September 23, 2009
(previously filed in Amendment No. 1 to the Form 8-K filed on September
25, 2009
).
|
|
|
Response
Letter (e-mail correspondence) of Georges Ugeux dated December 16,
2009.
|
Grafico Azioni Caraco (AMEX:CPD)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Caraco (AMEX:CPD)
Storico
Da Feb 2024 a Feb 2025
